Nuventym delivers authoritative consulting and business intelligence across specialty chemicals, pharmaceutical ingredients, and healthcare materials — purpose-built for the investment community.
Each engagement draws on deep chemistry knowledge, commercial acumen, and a rigorous analytical framework built over 25 years in the field.
Rigorous bottom-up market sizing, competitive landscape mapping, pricing dynamics, and demand forecasting across specialty chemical segments. Know what the market truly looks like — not just what reports say.
Expert commercial and technical due diligence for acquisitions, add-ons, and carve-outs in the specialty chemicals and ingredient space. We validate thesis assumptions, stress-test growth narratives, and surface hidden risks before close.
Sector landscape briefings, investment theme identification, and portfolio company strategy support. We help investors develop conviction in specialty chemicals opportunities and build defensible, long-term narratives.
Most market research tells you the "what." Nuventym tells you the "why" and "so what." Our advice is grounded in molecular-level chemistry knowledge, global supply chain experience, and decades of commercial context — not analyst desk research.
We translate complex chemistry into investment-grade intelligence that stands up to LP scrutiny and management due diligence alike.
Our work is designed for organizations where analytical rigor and domain accuracy directly drive capital decisions.
Commercial and technical diligence on target companies; value creation support for portfolio assets in chemicals and life sciences
Deep-dive sector intelligence, supply-demand dynamics, and competitive positioning analysis to support public and private equity decisions
Sector landscape briefings, theme identification, and investment thesis development for long-duration capital deployment in specialty materials
Sector-specific underwriting support, competitive moat assessment, and ongoing monitoring intelligence for credit positions in chemicals and pharma
Every engagement is tailored, confidential, and grounded in primary research — not recycled third-party data. We move at the pace your deals demand.
We begin with a structured briefing to understand your investment hypothesis, the specific questions that drive conviction, and your timeline. No generic deliverables.
We leverage our deep industry network — spanning producers, distributors, formulators, and regulators — to gather first-hand, proprietary intelligence not available in published sources.
Raw intelligence is stress-tested against financial, technical, and competitive frameworks. We distinguish signal from noise, identify key risks, and pressure-test assumptions.
Findings are packaged in clear, structured formats — IC memo-ready briefs, management interview frameworks, sector one-pagers, or full diligence reports — built for how your team works.
For retainer clients, we provide continuous sector monitoring, management call preparation, and ad-hoc advisory on portfolio company developments.
Generalist consultants read the same reports you can access. We bring 25 years of lived experience — in labs, in plants, in boardrooms, across three continents of the specialty chemicals world.
We understand chemistry at a molecular level — enabling us to evaluate product differentiation, switching costs, and defensibility in ways financial analysts cannot.
25 years of cultivated relationships with manufacturers, distributors, R&D leaders, and procurement heads — accessible to you through each engagement.
We communicate in investment language — IRR, moat analysis, pricing power, customer concentration — not just technical jargon. Outputs are built for IC presentations.
We operate under NDA and treat all engagement details, investment theses, and target company information with rigorous discretion.
Whether you're in the early stages of thesis development, deep in a live deal, or looking for an ongoing intelligence partner — we'd welcome the conversation. Engagements are structured around your needs and timeline.
All inquiries are handled with full confidentiality. Initial consultations available at no obligation.